Ignite Creation Date:
2024-06-16 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06459947
Status:
RECRUITING
Last Update Posted:
2024-06-17
First Post:
2024-06-11
Brief Title:
Effect of Cyanoacrylate and Concentrated Growth Factor on Palatal Donor Site
Sponsor:
Yuzuncu Yıl University
Organization:
Yuzuncu Yıl University
Study Overview
Official Title:
Effect of Cyanoacrylate and Concentrated Growth Factor on Wound Healing and Patient Comfort at the Palatal Donor Site
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this planned randomized controlled clinical study is to evaluate the morbidity of the palatal donor area after free gingival graft FGG operations In this study wound healing and pain levels in the palatal region will be evaluated after cyanoacrylate and concentrated growth factor CGF applications
Detailed Description:
Free gingival graft obtained in the palatal region causes morbidity Therefore clinicians try to overcome these difficulties by isolating the wound in the palatal region from the oral environment andor accelerating wound healing
Periodontal dressings acrylic stents hemostatic agents surgical sponges platelet concentrates low-level laser therapy photobiomodulation cyanoacrylate tissue adhesives and hyaluronic acid are some of the methods used for donor site management or to accelerate healing
Cyanoacrylate adhesives form an adhesive film through rapid polymerization triggered by the hydroxyl groups on the surfaces to which they are applied They have both bacteriostatic and hemostatic properties
In recent years it has been observed that the use of platelet concentrates such as Platelet Rich Plasma PRP Platelet Rich Fibrin PRF and autogenous products such as CGF concentrated growth factor in periodontal treatments has increased
CGF is obtained by centrifuging blood in four different cycles and times This product contains a relatively intact fibrin clot containing platelets leukocytes various growth factors and cytokines CGF can be applied as a carrier of growth factors andor a barrier membrane to aid tissue regeneration and wound healing in clinical applications
The aim of this planned randomized controlled clinical study is to evaluate the morbidity of the palatal donor area after FGG operations In this study wound healing and pain levels in the palatal region will be evaluated after cyanoacrylate and CGF applications
Periodontal dressings acrylic stents hemostatic agents surgical sponges platelet concentrates low-level laser therapy photobiomodulation cyanoacrylate tissue adhesives and hyaluronic acid are some of the methods used for donor site management or to accelerate healing
Cyanoacrylate adhesives form an adhesive film through rapid polymerization triggered by the hydroxyl groups on the surfaces to which they are applied They have both bacteriostatic and hemostatic properties
In recent years it has been observed that the use of platelet concentrates such as Platelet Rich Plasma PRP Platelet Rich Fibrin PRF and autogenous products such as CGF concentrated growth factor in periodontal treatments has increased
CGF is obtained by centrifuging blood in four different cycles and times This product contains a relatively intact fibrin clot containing platelets leukocytes various growth factors and cytokines CGF can be applied as a carrier of growth factors andor a barrier membrane to aid tissue regeneration and wound healing in clinical applications
The aim of this planned randomized controlled clinical study is to evaluate the morbidity of the palatal donor area after FGG operations In this study wound healing and pain levels in the palatal region will be evaluated after cyanoacrylate and CGF applications
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None